Latest:
The Exciting Future of NSCLC Treatment
Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.
Authors
Kirollos Hanna, PharmD, BCPS, BCOP
Latest:
Comorbidities, Quality of Life, Efficacy, and Safety in Expanding Subcutaneous Treatment Use
Panelists discuss how subcutaneous checkpoint inhibitors are appropriate for nearly all patients except those with severe cachexia limiting injection sites, with patient conversations emphasizing equivalent efficacy data, safety profiles, quality of life benefits including potential home administration, and the option to maintain IV therapy for patients who prefer their current regimen.
Young Son, PGY3
Latest:
Dr Son on Urinary and Bowel Anastomotic Leak in Bladder Cancer
Young Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.
Richard L. Martin III, MD, MPH
Latest:
A Challenge to Medical Oncology Training Programs: Promote Equity in Training
In her 2020 American Society of Clinical Oncology presidential address, “Equity: Every patient. Every day. Everywhere,” Lori J. Pierce, MD, challenges medical oncology to imagine a future when equity is considered a humanistic standard of oncology practice.
Michael J. Fallon, MD
Latest:
Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma
Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.
Peter Riedell, MD
Peter Riedell, MD, is an associate professor of medicine in the Section of Hematology/Oncology at the University of Chicago.
Latest:
Overcoming Barriers and Improving CAR T Care in Academic and Community Settings
Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.